182 related articles for article (PubMed ID: 33956029)
1. A targeted covalent small molecule inhibitor of HIV-1 fusion.
Zhou G; He L; Li KH; Pedroso CCS; Gochin M
Chem Commun (Camb); 2021 May; 57(37):4528-4531. PubMed ID: 33956029
[TBL] [Abstract][Full Text] [Related]
2. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
Lu L; Yu F; Cai L; Debnath AK; Jiang S
Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors.
Zhou G; Chu S; Nemati A; Huang C; Snyder BA; Ptak RG; Gochin M
Eur J Med Chem; 2019 Jan; 161():533-542. PubMed ID: 30390441
[TBL] [Abstract][Full Text] [Related]
4. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.
Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P
Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370
[TBL] [Abstract][Full Text] [Related]
5. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
6. Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library.
Whitby LR; Boyle KE; Cai L; Yu X; Gochin M; Boger DL
Bioorg Med Chem Lett; 2012 Apr; 22(8):2861-5. PubMed ID: 22424973
[TBL] [Abstract][Full Text] [Related]
7. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
He XY; Lu L; Qiu J; Zou P; Yu F; Jiang XK; Li L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2013 Dec; 21(23):7539-48. PubMed ID: 23673219
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.
Zhou G; Wu D; Hermel E; Balogh E; Gochin M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1500-3. PubMed ID: 20153190
[TBL] [Abstract][Full Text] [Related]
9. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
10. Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection.
Huhmann S; Nyakatura EK; Rohrhofer A; Moschner J; Schmidt B; Eichler J; Roth C; Koksch B
Chembiochem; 2021 Dec; 22(24):3443-3451. PubMed ID: 34605595
[TBL] [Abstract][Full Text] [Related]
11. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.
Zhou G; Wu D; Snyder B; Ptak RG; Kaur H; Gochin M
J Med Chem; 2011 Oct; 54(20):7220-31. PubMed ID: 21928824
[TBL] [Abstract][Full Text] [Related]
12. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
[TBL] [Abstract][Full Text] [Related]
13. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
14. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
15. Targeting a Conserved Lysine in the Hydrophobic Pocket of HIV-1 gp41 Improves Small Molecule Antiviral Activity.
He L; Zhou G; Sofiyev V; Garcia E; Nguyen N; Li KH; Gochin M
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560708
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
Mostashari Rad T; Saghaie L; Fassihi A
Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
[TBL] [Abstract][Full Text] [Related]
17. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
18. HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.
Xiao T; Frey G; Fu Q; Lavine CL; Scott DA; Seaman MS; Chou JJ; Chen B
Nat Chem Biol; 2020 May; 16(5):529-537. PubMed ID: 32152540
[TBL] [Abstract][Full Text] [Related]
19. Dimeric C34 Derivatives Linked through Disulfide Bridges as New HIV-1 Fusion Inhibitors.
Kobayakawa T; Ebihara K; Honda Y; Fujino M; Nomura W; Yamamoto N; Murakami T; Tamamura H
Chembiochem; 2019 Aug; 20(16):2101-2108. PubMed ID: 31012222
[TBL] [Abstract][Full Text] [Related]
20. A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.
Wensel D; Sun Y; Davis J; Li Z; Zhang S; McDonagh T; Fabrizio D; Cockett M; Krystal M
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
